Company intelligence / Profile preview

HL Genomix

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

HL Genomix is a South Korean biotechnology company specializing in precision medicine through advanced genomic analysis and molecular diagnostics. The company leverages next-generation sequencing (NGS) technologies to provide comprehensive genetic testing services for oncology, rare diseases, and personalized health management. By integrating bioinformatics with clinical data, HL Genomix aims to deliver actionable insights that support targeted therapy selection and early disease detection. Their portfolio includes specialized diagnostic kits and screening services designed to improve patient outcomes through individualized medical approaches.

Therapeutic areas: OncologyRare DiseasesInfectious Diseases
Modalities: Next-generation sequencingMolecular diagnostics
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on HL Genomix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL Genomix.

Explore the full profile